NIAID

The H. pylori machinery that “injects” an oncoprotein into stomach cells contributes to the development of gastric cancer, Vanderbilt researchers demonstrate.

A cellular RNA quality control mechanism was known to restrict replication of RNA viruses. Vanderbilt researchers have discovered it is also antiviral against DNA viruses.

Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19.

In late July, Vanderbilt University Medical Center will begin recruiting up to 1,000 volunteers in a late-stage study of an experimental COVID-19 vaccine developed by Moderna Inc. in collaboration with the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.

An experimental coronavirus vaccine stimulated robust immune responses against SARS-CoV-2, the virus that causes COVID-19, and raised no serious safety concerns in an early-stage clinical trial.

Vanderbilt immunologists have discovered that the protein Nur77 is part of a control mechanism that guards against autoimmunity in natural killer T cells.

Bacterial invasion of vaginal cells sets up a protective niche and a reservoir for recurrent urinary tract infections, Vanderbilt researchers demonstrated.